Boston Scientific Corp. Hits New 52-Week Low at $60.59

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 60.59 on April 9, 2026. This marks a notable decline in the stock's performance, with a one-year decrease of 20.85%, contrasting sharply with the S&P 500's gain of 25.06% over the same period. As a large-cap company in the retailing industry, Boston Scientific boasts a market capitalization of approximately USD 121.94 billion. The company's price-to-earnings (P/E) ratio stands at 36.00, indicating its valuation relative to earnings. Additionally, Boston Scientific has a debt-to-equity ratio of 0.39, suggesting a moderate level of debt compared to its equity. The return on equity is reported at 13.88%, reflecting the company's ability to generate profit from its shareholders' investments. Despite the current price movement, the stock's performance metrics highlight its position within the market, with a price-to-book ratio of 5.03 and a dividend yield of 0.00%. The stock's previous 52-week high was recorded at USD 109.50.